Current Report — Form 8-K Filing Table of Contents
Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 36K
2: EX-99.1 Press Release of Bristol-Myers Squibb Company HTML 141K
Dated April 29, 2021
3: EX-99.2 Certain Supplemental Information HTML 406K
4: EX-99.3 Presentation Materials of Bristol-Myers Squibb HTML 24K
Company Dated April 29, 2021
11: R1 Document and Entity Information Document and HTML 58K
Entity Information
13: XML IDEA XML File -- Filing Summary XML 13K
10: XML XBRL Instance -- bmy-20210429_htm XML 35K
12: EXCEL IDEA Workbook of Financial Reports XLSX 6K
6: EX-101.CAL XBRL Calculations -- bmy-20210429_cal XML 8K
7: EX-101.DEF XBRL Definitions -- bmy-20210429_def XML 26K
8: EX-101.LAB XBRL Labels -- bmy-20210429_lab XML 101K
9: EX-101.PRE XBRL Presentations -- bmy-20210429_pre XML 48K
5: EX-101.SCH XBRL Schema -- bmy-20210429 XSD 16K
14: JSON XBRL Instance as JSON Data -- MetaLinks 16± 25K
15: ZIP XBRL Zipped Folder -- 0000014272-21-000124-xbrl Zip 77K
(State
or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S Employer Identification No.)
i430 E. 29th Street, i14th Floor
iNew York, iNY, i10016
(Address
of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (i212) i546-4000
_____________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
i☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
Stock, $0.10 Par Value
iBMY
iNew York Stock Exchange
i1.000%
Notes due 2025
iBMY25
iNew York Stock Exchange
i1.750%
Notes due 2035
iBMY35
iNew York Stock Exchange
iCelgene
Contingent Value Rights
iCELG RT
iNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On April 29, 2021, Bristol-Myers Squibb Company (the “Company”) issued
a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2021. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Also furnished pursuant to this Item 2.02 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety is certain
supplemental information (the “Supplemental Information”) posted on the Company’s website at www.bms.com.
Item 7.01 Regulation FD Disclosure.
On April 29, 2021, the Company posted on its website
at www.bms.com a presentation (the “Bristol Myers Presentation”) on certain financial and operating initiatives available for viewing during the Company’s conference call and webcast announcing its financial results for the first quarter of 2021 at 9:00 a.m. Eastern time on April 29, 2021. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Bristol Myers Presentation includes references to non-GAAP financial information. Reconciliations between the non-GAAP
financial measures and the comparable GAAP financial measures are available in the Supplemental Information, which is included as Exhibit 99.2 hereto, and the reasons for the presentation of such non-GAAP financial measures are available in the Earnings Press Release, which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Supplemental Information and the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website
at any time.
Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.3, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information
in this this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are furnished as part of this Current Report on Form 8-K:
The
cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
